0
0
May 1, 2025 – The U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel), a first-of-its-kind gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe genetic skin disorder. The therapy, developed by Abeona Therapeutics, offers hope to patients who previously relied solely on wound management and palliative care.
How It Works
RDEB is caused by mutations in the COL7A1 gene, which produces collagen essential for binding skin layers. Patients experience chronic, painful blisters, wounds, and a high risk of infections and complications. Zevaskyn uses a patient’s own skin cells, genetically modified to restore functional collagen production. These cells are grown into sheets and surgically grafted onto wounds, promoting healing and reducing pain.
Clinical Success
In trials, 81% of large, persistent wounds treated with Zevaskyn showed ≥50% healing within six months, compared to 16% with standard care. Earlier studies demonstrated benefits lasting up to eight years post-treatment, marking a potential lifelong improvement for many patients.
Expert Insight
“This therapy offers long-term healing, reduced pain, and lower infection risk,” said Dr. Amy Paller, a pediatric dermatologist involved in the trials. “It’s a transformative step for RDEB patients.”
Safety and Availability
Common side effects include procedural pain and itching, while rare risks include cancer (requiring lifelong monitoring). Zevaskyn will be available through specialized EB treatment centers in the U.S. by late 2025.
Disclaimer: This article summarizes information from a WebMD report and Abeona Therapeutics’ press release. Consult a healthcare provider for medical advice. Individual results may vary, and potential risks/benefits should be discussed with a qualified physician.
Citations:
